Loading clinical trials...
Loading clinical trials...
Real-Time Continuous Glucose Monitoring to Aid Weight Loss in Prediabetes
The primary objective of this study is to determine whether intermittent use of continuous glucose monitor will facilitate weight loss in individuals who are overweight/obese with prediabetes.
Continuous glucose monitoring (CGM) has revolutionized the treatment of patients on intensive insulin therapy and its utility can also be harnessed to help individuals with prediabetes make healthful lifestyle changes. Successful weight loss requires adherence to lower calories, regular exercise, and self-monitoring. This proposal will test the hypothesis that intermittent CGM will facilitate all of these components for successful weight loss by functioning as a continuous self-monitor and guiding healthful food choices and physical activity.
Age
18 - 99 years
Sex
ALL
Healthy Volunteers
Yes
Stanford
Stanford, California, United States
Start Date
August 1, 2019
Primary Completion Date
December 31, 2021
Completion Date
December 31, 2021
Last Updated
January 31, 2023
12
ACTUAL participants
CGM
DEVICE
Dietitian
OTHER
Lead Sponsor
Stanford University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06252038